CompletedPhase 4NCT01617070
Effects of Kuvan on Melatonin Secretion
Studying Disorder of phenylalanine metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Southern California
- Principal Investigator
- Shoji Yano, M.D., Ph.D., M.DUSC Keck School of Medicine, Dept. of Pediatrics, Genetics Division
- Intervention
- Kuvan(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2014
Study locations (1)
- Keck School of Medicine, Clinical Trials Unit at Keck Medical Center of USC, Los Angeles, California, United States
Collaborators
BioMarin Pharmaceutical
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01617070 on ClinicalTrials.govOther trials for Disorder of phenylalanine metabolism
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07220265Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU CarriersUniversity of Missouri-Columbia
- RECRUITINGPHASE2NCT06637514A Phase 2 Study of JNT-517 in Adolescent Participants With PhenylketonuriaOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGPHASE3NCT06628128A Study to Evaluate the Long-Term Safety and Efficacy of JNT-517 in Participants With PhenylketonuriaOtsuka Pharmaceutical Development & Commercialization, Inc.
- RECRUITINGNANCT05579548A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and BreastfeedingBioMarin Pharmaceutical
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04480567AAV Gene Therapy Study for Subjects with PKUBioMarin Pharmaceutical